Blurbs

Analysts Are Bullish on Top Healthcare Stocks: Provention Bio (PRVB), Applied Molecular Transport (AMTI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Provention Bio (PRVBResearch Report), Applied Molecular Transport (AMTIResearch Report) and Rocket Pharmaceuticals (RCKTResearch Report) with bullish sentiments.

Provention Bio (PRVB)

SVB Securities analyst Thomas Smith reiterated a Buy rating on Provention Bio on May 19 and set a price target of $16.00. The company’s shares closed last Friday at $3.96, close to its 52-week low of $3.40.

According to TipRanks.com, Smith has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -30.9% and a 14.6% success rate. Smith covers the Healthcare sector, focusing on stocks such as Connect Biopharma Holdings, Madrigal Pharmaceuticals, and Prometheus Biosciences.

Currently, the analyst consensus on Provention Bio is a Strong Buy with an average price target of $15.25, a 278.4% upside from current levels. In a report issued on May 5, Chardan Capital also reiterated a Buy rating on the stock with a $22.50 price target.

See the top stocks recommended by analysts >>

Applied Molecular Transport (AMTI)

SVB Securities analyst Joseph Schwartz reiterated a Buy rating on Applied Molecular Transport on May 19 and set a price target of $21.00. The company’s shares closed last Friday at $3.18, equals to its 52-week low of $3.18.

According to TipRanks.com, Schwartz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.0% and a 24.9% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Crinetics Pharmaceuticals, and Ultragenyx Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Applied Molecular Transport with a $35.50 average price target, implying a 1002.5% upside from current levels. In a report released yesterday, Bank of America Securities also maintained a Buy rating on the stock with a $10.00 price target.

Rocket Pharmaceuticals (RCKT)

In a report issued on May 19, Mani Foroohar from SVB Securities reiterated a Buy rating on Rocket Pharmaceuticals, with a price target of $66.00. The company’s shares closed last Friday at $10.70, close to its 52-week low of $7.57.

According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -23.7% and a 32.9% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Arrowhead Pharmaceuticals, and 4D Molecular Therapeutics.

Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $62.33, a 494.8% upside from current levels. In a report issued on May 5, William Blair also maintained a Buy rating on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on PRVB:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos